A carregar...
Publicação
How can rezolve medical best position itself to secure EUR 1-1.5 muillion in growth capital at optimal terms?
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 463.5 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
The aim of this study was to examine how Rezolve Medical can secure early-stage growth capital within the European MedTech investment landscape. To achieve this, the study combined a structured review of peer reviewed journal articles and grey literature with four semi structured interviews conducted with European healthcare investors. The findings show that investment decisions are driven by the reduction of regulatory, clinical, reimbursement, and operational uncertainty rather than by technical novelty alone. The study outlines how Rezolve can structure a 1-to-1.5-million-euro funding round by aligning evidence generation, milestone timing, and governance preparation with investor evaluation patterns in early stage MedTech.
Descrição
Palavras-chave
MedTech Fundraising Reimbursement Market entry Early-stage investment Commercialization Financing Orthotics Entrepreneurial finance Personalized medical devices Startup valuation